Efficacy of lenalidomide in a patient with systemic mastocytosis associated with SF3B1-mutant myelodysplastic syndrome

Leuk Lymphoma. 2021 Dec;62(12):3027-3030. doi: 10.1080/10428194.2021.1941925. Epub 2021 Jun 21.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lenalidomide / therapeutic use
  • Mastocytosis, Systemic* / complications
  • Mastocytosis, Systemic* / diagnosis
  • Mastocytosis, Systemic* / drug therapy
  • Mutation
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / drug therapy
  • Phosphoproteins / genetics
  • RNA Splicing Factors / genetics

Substances

  • Phosphoproteins
  • RNA Splicing Factors
  • SF3B1 protein, human
  • Lenalidomide